Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Mechlorethamine Clear all
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients

NCT00507442
View directory record Official record
Conditions
Multiple Myeloma
Interventions
VELCADE (bortezomib), dexamethasone, cyclophosphamide, Revlimid (lenalidomide)
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Denver, Colorado • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Sep 10, 2026, 4:12 PM EDT
Recruiting Phase 2 Interventional

BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)

NCT04187105
View directory record Official record
Conditions
Acute Leukemia, MDS
Interventions
Conditioning regimen with half-matched (haploidentical) stem cell transplant, Conditioning regimen with half-matched (haploidentical) stem cell transplant, Conditioning regimen with half-matched (haploidentical) stem cell transplant, Conditioning regimen with half-matched (haploidentical) stem cell transplant
Radiation · Drug · Device + 1 more
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 10, 2026, 4:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma

NCT01535924
View directory record Official record
Conditions
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma
Interventions
gemcitabine hydrochloride, bendamustine hydrochloride
Drug
Lead sponsor
Beth Christian
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Atlanta, Georgia • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Sep 10, 2026, 4:12 PM EDT
Not listed Phase 1Phase 2 Interventional

Biological Therapy in Treating Women With Metastatic Breast Cancer

NCT00002780
View directory record Official record
Conditions
Breast Cancer
Interventions
aldesleukin, cytokine therapy, sargramostim, carboplatin, cyclophosphamide, thiotepa, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
St. Luke's Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 10, 2026, 4:12 PM EDT
Suspended Phase 1 Interventional

Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome

NCT03494569
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Hematopoietic Cell Transplantation Recipient, Minimal Residual Disease, Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
Interventions
Fludarabine, Laboratory Biomarker Analysis, Melphalan, Total Marrow Irradiation
Drug · Other · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
12 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 10, 2026, 4:12 PM EDT
Completed Phase 2 Interventional Results available

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

NCT01216683
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, Bendamustin, bortezomib, lenalidomide
Biological · Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
227
States / cities
Greenbrae, California • Salinas, California • Stanford, California + 158 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Sep 10, 2026, 4:12 PM EDT
Recruiting Phase 2 Interventional

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

NCT06318897
View directory record Official record
Conditions
Stage 1 cT1b-T1cN0M0, Triple Negative Breast Cancer
Interventions
Carboplatin, Paclitaxel, Pembrolizumab, Doxorubicin, Cyclophosphamide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 10, 2026, 4:12 PM EDT
Not listed Phase 2 Interventional Results available

Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer

NCT00499603
View directory record Official record
Conditions
Breast Cancer
Interventions
Paclitaxel, 5-Fluorouracil, Epirubicin, Cyclophosphamide, RAD001
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Sep 10, 2026, 4:12 PM EDT
Active, not recruiting Phase 1 Interventional

CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission

NCT05707273
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia
Interventions
Autologous Anti-CD19 CAR-expressing T Lymphocytes, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, Fludarabine, Leukapheresis, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
55 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 10, 2026, 4:12 PM EDT
Completed Phase 2 Interventional Results available

Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma

NCT00101010
View directory record Official record
Conditions
Lymphoma
Interventions
Filgrastim, Pegfilgrastim, Rituximab, Cyclophosphamide, Pegylated liposomal doxorubicin hydrochloride, Prednisone, Vincristine Sulfate
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
61 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
7
States / cities
Fort Smith, Arkansas • Grand Rapids, Michigan • Kalamazoo, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 10, 2026, 4:12 PM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer

NCT03726879
View directory record Official record
Conditions
Breast Cancer
Interventions
Atezolizumab, Placebo, Doxorubicin, Cyclophosphamide, Paclitaxel, Trastuzumab, Pertuzumab, Trastuzumab Emtansine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Kansas City, Missouri • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Sep 10, 2026, 4:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

NCT00576979
View directory record Official record
Conditions
Leukemia
Interventions
cyclophosphamide, etoposide, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, intensity-modulated radiation therapy, tomotherapy
Drug · Procedure · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
7 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 10, 2026, 4:12 PM EDT
Withdrawn Phase 2 Interventional

Allogeneic Transplantation Using Mini-Conditioning for Treatment of Stage IV Breast Cancer

NCT00006261
View directory record Official record
Conditions
Breast Cancer
Interventions
therapeutic allogeneic lymphocytes, cyclophosphamide, docetaxel, doxorubicin hydrochloride, fludarabine phosphate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 60 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 9, 2010 · Synced Sep 10, 2026, 4:12 PM EDT
Completed Phase 1 Interventional

Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

NCT00070083
View directory record Official record
Conditions
Lymphoma
Interventions
oblimersen sodium, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
Biological · Drug
Lead sponsor
British Columbia Cancer Agency
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2009 · Synced Sep 10, 2026, 4:12 PM EDT
Completed Phase 1Phase 2 Interventional

Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma

NCT00038168
View directory record Official record
Conditions
Prostate Cancer
Interventions
Estramustine, Taxol
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Sep 10, 2026, 4:12 PM EDT
Completed Phase 2 Interventional

Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer

NCT02593227
View directory record Official record
Conditions
Breast Cancer
Interventions
Low dose FRα vaccine, Cyclophosphamide, High dose FRα vaccine
Biological · Drug
Lead sponsor
Marker Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
11
States / cities
Tampa, Florida • Westwood, Kansas • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2021 · Synced Sep 10, 2026, 4:12 PM EDT
Recruiting Phase 2 Interventional

A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma

NCT07454382
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elranatamab-bcmm, Cyclophosphamide
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 10, 2026, 4:12 PM EDT
Active, not recruiting Phase 1 Interventional

Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH

NCT04540380
View directory record Official record
Conditions
Renal Failure
Interventions
Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab, Combined bone marrow and kidney transplant
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 10, 2026, 4:12 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia

NCT01885689
View directory record Official record
Conditions
Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission, Myelodysplastic Syndrome, Secondary Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Therapy-Related Myelodysplastic Syndrome
Interventions
clofarabine, melphalan, allogeneic hematopoietic stem cell transplantation, tacrolimus, sirolimus, Pharmacological Study
Drug · Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 10, 2026, 4:12 PM EDT
Completed Phase 1 Interventional

Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer

NCT00719173
View directory record Official record
Conditions
Breast Cancer, Nausea and Vomiting
Interventions
aprepitant, cyclophosphamide, placebo
Drug · Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 3, 2024 · Synced Sep 10, 2026, 4:12 PM EDT
Recruiting Phase 2 Interventional

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Total-Body Irradiation, Venetoclax
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
336
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 259 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 10, 2026, 4:12 PM EDT
Not listed Phase 2 Interventional

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

NCT00004903
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, recombinant interferon alfa, cisplatin, cyclophosphamide, cytarabine, etoposide, melphalan, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Robert H. Lurie Cancer Center
Other
Eligibility
Up to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Sep 10, 2026, 4:12 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

NCT03301350
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer
Interventions
Carboplatin, Paclitaxel, Doxorubicin, Cyclophosphamide, Pegfilgrastim, Filgrastim
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 74 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Rockford, Illinois • Madison, Wisconsin • Milwaukee, Wisconsin + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 10, 2026, 4:12 PM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor

NCT06154590
View directory record Official record
Conditions
Metastatic Breast Cancer, Tumor, Muscle Neoplasms, Chronic Pain
Interventions
Method(s)1 Attribution, Method(s)2 Attribution,
Drug
Lead sponsor
DR. DIANE CHISESI NFS. MD. PHD.
Other
Eligibility
44 Years to 59 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 3, 2023 · Synced Sep 10, 2026, 4:12 PM EDT